CORDIS
EU research results

CORDIS

English EN
HARMONIzation and integrative analysis of regional, national and international Cohorts on primary Sjögren’s Syndrome (pSS) towards improved stratification, treatment and health policy making

HARMONIzation and integrative analysis of regional, national and international Cohorts on primary Sjögren’s Syndrome (pSS) towards improved stratification, treatment and health policy making

Objective

HarmonicSS vision is to create an International Network and Alliance of partners and cohorts, entrusted with the mission of addressing the unmet needs in primary Sjogren Syndrome; working together to create and maintain a platform with open standards and tools, designed to enable secure storage, governance, analytics, access control and controlled sharing of information at multiple levels along with methods to make results of analyses and outcomes comparable across centers and sustainable through Rheumatology associations. The overall idea of the HarmonicSS project is to bring together the largest well characterized regional, national and international longitudinal cohorts of patients with Primary Sjögren’s Syndrome (pSS) including those participating in clinical trials, and after taking into consideration the ethical, legal, privacy and IPR issues for sharing data from different countries, to semantically interlink and harmonize them into an integrative pSS cohort structure on the cloud. Upon this harmonized cohort, services for big data mining, governance and visual analytics will be integrated, to address the identified clinical and health policy pSS unmet needs. In addition, tools for specific diagnostic procedures (e.g. ultrasonography image segmentation), patient selection for clinical trials and training will be also provided. The users of the HarmonicSS platform are researchers (basic/translational), clinicians, health policy makers and pharma companies. pSS is relevant not only due to its clinical impact but also as one of the few “model” diseases to link autoimmunity, cancer development (lymphoproliferation) and the pathogenetic role of infection. Thus, the study of pSS can facilitate research in many areas of medicine; for this reason, the possibility for sustainability and expandability of the platform is enhanced. Moreover, pSS has a significant impact on the healthcare systems, similar to that of rheumatoid arthritis.

Coordinator

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Address

6 Christou Lada Str
10561 Athina

Greece

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 761 247,50

Participants (36)

Sort alphabetically

Sort by EU Contribution

Expand all

INSTITUTE OF COMMUNICATION AND COMPUTER SYSTEMS

Greece

EU Contribution

€ 411 250

PANEPISTIMIO IOANNINON

Greece

EU Contribution

€ 765 000

TECHNOLOGICAL EDUCATIONAL INSTITUTE OF CRETE

Greece

EU Contribution

€ 202 500

ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS

Greece

EU Contribution

€ 200 000

UNIVERSITA DEGLI STUDI DI UDINE

Italy

EU Contribution

€ 362 500

UNIVERSITA DI PISA

Italy

EU Contribution

€ 280 740

UNIVERSITA DEGLI STUDI DI PERUGIA

Italy

EU Contribution

€ 275 793,75

UNIVERSITA DEGLI STUDI DELL'AQUILA

Italy

EU Contribution

€ 275 175

UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA

Italy

EU Contribution

€ 279 503,75

SCUOLA SUPERIORE DI STUDI UNIVERSITARI E DI PERFEZIONAMENTO S ANNA

Italy

EU Contribution

€ 200 000

MEDIZINISCHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 277 648,75

CHARITE - UNIVERSITAETSMEDIZIN BERLIN

Germany

EU Contribution

€ 277 031,25

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

EU Contribution

€ 290 000

GOTTFRIED WILHELM LEIBNIZ UNIVERSITAET HANNOVER

Germany

EU Contribution

€ 175 000

THE UNIVERSITY OF BIRMINGHAM

United Kingdom

EU Contribution

€ 275 793,75

QUEEN MARY UNIVERSITY OF LONDON

United Kingdom

EU Contribution

€ 280 122,50

UNIVERSITY OF NEWCASTLE UPON TYNE

United Kingdom

EU Contribution

€ 279 503,75

CONSORCI INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER

Spain

EU Contribution

€ 280 122,50

FUNDACIÓN PARA LA INVESTIGACIÓN E INNOVACIÓN BIOMÉDICA DE ATENCIÓN PRIMARIA

Spain

EU Contribution

€ 93 750

ATOS SPAIN SA

Spain

EU Contribution

€ 358 750

UNIVERSITE DE BRETAGNE OCCIDENTALE

France

EU Contribution

€ 276 411,25

UNIVERSITE PARIS-SUD

France

EU Contribution

€ 308 250

LUNDS UNIVERSITET

Sweden

UPPSALA UNIVERSITET

Sweden

EU Contribution

€ 277 401,25

ACADEMISCH ZIEKENHUIS GRONINGEN

Netherlands

EU Contribution

€ 278 885

UNIVERSITAIR MEDISCH CENTRUM UTRECHT

Netherlands

EU Contribution

€ 277 031,25

STICHTING NEDERLANDS INSTITUUT VOOR ONDERZOEK VAN DE GEZONDHEIDSZORG

Netherlands

EU Contribution

€ 228 750

EUROPEAN LEAGUE AGAINST RHEUMATISM

Switzerland

UNIVERSITETET I BERGEN

Norway

EU Contribution

€ 276 411,25

UNIVERSITE LIBRE DE BRUXELLES

Belgium

EU Contribution

€ 276 411,25

ISTRAZIVACKO RAZVOJNI CENTAR ZA BIOINZENJERING BIOIRC DOO

Serbia

EU Contribution

€ 206 250

OKLAHOMA MEDICAL RESEARCH FOUNDATION

United States

EU Contribution

€ 290 633,75

SJOGREN'S SYNDROME FOUNDATION INC.

United States

EU Contribution

€ 178 750

MARIOS LYMARAKIS KAI SIA EE

Greece

EU Contribution

€ 182 500

HAROKOPIO UNIVERSITY

Greece

EU Contribution

€ 279 132,50

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

France

EU Contribution

€ 60 500

Project information

Grant agreement ID: 731944

Status

Ongoing project

  • Start date

    1 January 2017

  • End date

    30 June 2020

Funded under:

H2020-EU.3.1.1.

  • Overall budget:

    € 10 193 125

  • EU contribution

    € 9 998 750

Coordinated by:

ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON

Greece